Sonoma Pharmaceuticals, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended March 31, 2020; filed July 10, 2020. The request refers to 2019 Q4, but this filing reports the full fiscal year, not a standalone quarter. Sonoma develops and sells stabilized hypochlorous acid (HOCl) products for human and animal health in 53 countries.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Total revenue | $18.936 million | $18.970 million |
| Product revenue | $17.777 million | $17.881 million |
| Service revenue | $1.159 million | $1.089 million |
| Gross profit / margin | $8.333 million / 44% | $8.880 million / 47% |
| Operating expenses | $15.004 million | $20.138 million |
| Operating loss | $6.671 million | $11.258 million |
| Net loss | $2.946 million | $11.798 million |
| Net cash used in operations | $4.591 million | $11.717 million |
| Cash and cash equivalents at year end | $3.691 million | $3.689 million |
| Working capital at year end | $7.518 million | $8.905 million |
Net loss per share was $1.99, compared with $12.77 in FY2019. Selling, general and administrative expense fell 27% to $13.665 million; research and development expense declined 12% to $1.339 million. FY2020 gross margin was reduced in part by a $510,000 obsolete-inventory adjustment in Mexico. Product gross margin was 43%, versus 48%; service gross margin improved to 55%, from 31%.
Cash from investing activities was $3.644 million, mainly from asset-sale proceeds; financing activities provided $1.029 million, including $1.376 million net proceeds from a common-stock offering. Contractual obligations reported at March 31, 2020 totaled $879,000, all due within one year: $481,000 of long-term debt principal, $147,000 of finance leases and $251,000 of operating leases. The balance sheet reports $481,000 of current debt and no long-term debt.
Changes versus FY2019
- Revenue was nearly flat, but regional mix shifted: U.S. product revenue declined 27% to $6.633 million; Latin American product revenue declined 7% to $3.684 million; Europe and rest-of-world product revenue rose 53% to $7.460 million.
- Lower operating expenses drove a $4.587 million improvement in operating loss. Net loss narrowed by $8.852 million, helped also by $3.572 million in gains on asset sales to Petagon and MicroSafe.
- Operating cash outflow improved substantially but remained significant. Accounts receivable increased, and the company recorded $1.004 million in doubtful-account provision in its cash-flow reconciliation.
- One customer accounted for 15% of FY2020 net revenue and another for 11%; in FY2019, the largest customer concentration was reported as 18% and 10%.
Outlook, risks and unusual items
- Going concern: The auditor’s report includes an explanatory paragraph stating that substantial doubt exists about the company’s ability to continue as a going concern. Management says additional capital may be needed and cannot assure financing will be available on acceptable terms. No quantified break-even or revenue guidance is provided.
- Management outlook: Management expects losses for the next two quarters as it absorbs restructuring and one-time costs, while pursuing lower costs and improved revenue and margins. It expects the facility consolidation to reduce overhead after these costs.
- Restructuring after year end: On June 24, 2020, Sonoma closed its Petaluma manufacturing facility and moved U.S. manufacturing to Zapopan, Mexico; corporate functions moved to Woodstock, Georgia. The filing says the move is expected to reduce overhead and manufacturing costs, but the savings are not quantified.
- Invekra transition: Invekra-related revenue was $3.581 million in FY2020, about 19% of total revenue. Reduced-price manufacturing arrangements were expected to end in October 2020, with supply anticipated through December; management expects Invekra revenue to decline thereafter, with margins potentially improving.
- COVID-19: Restrictions impeded in-person U.S. dermatology sales and reduced division revenue in spring 2020. Management reported some improvement in June but said the future effect was uncertain. Interest in potential U.S. distribution partners also increased, according to management.
- Subsequent financing and transactions: After year end, Sonoma received $1.490 million from warrant exercises, a $1.300 million PPP loan and proceeds from selling its Micromed Laboratories division. The PPP loan is subject to forgiveness conditions; full or partial forgiveness is not assured. The Micromed sale agreement provided for $850,000 consideration, including cash at closing, future testing-service value and escrow, subject to adjustments.
- Other material risks: Dependence on key customers and partners, reimbursement and pricing pressure, receivable collection, international operations and currency movements, regulatory compliance, manufacturing execution, competition, intellectual-property protection and the need for additional capital.
- Audit and controls: The auditor gave an unqualified opinion on the financial statements, with the going-concern emphasis noted above. Management concluded disclosure controls and internal control over financial reporting were effective as of March 31, 2020.
Key facts for investors to verify
- Available cash, subsequent warrant and PPP proceeds, near-term cash burn, and the company’s ability to obtain further financing given the going-concern warning.
- Actual savings and one-time costs from the Petaluma closure and manufacturing consolidation, including quality and regulatory performance at the Mexico facility.
- Replacement revenue and margin effects as Invekra’s reduced-price supply arrangement ends.
- Receivable quality and collection: the filing’s balance-sheet and risk-factor figures show FY2019 net receivables of $3.481 million, while the accounts-receivable note lists $3.841 million; the filing text does not provide a clear reconciliation.
- Whether reported asset-sale gains, inventory adjustments and doubtful-account provisions are nonrecurring, and the effect of these items on underlying operating performance and cash generation.
- PPP loan forgiveness status and final consideration received or retained under the Micromed sale.